Pharmaceutical CDMO Market Size, Share & Trends Analysis Report By Product (API, Drug Product), By Workflow (Clinical, Commercial), By Application (Oncology, Infectious Diseases, Neurological Disorders), By Region, And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                        1.1.1. Regional Scope
                        1.1.2. Estimates and Forecast Timeline
                    1.2. Research Methodology
                    1.3. Information Procurement
                        1.3.1. Purchased Database
                        1.3.2. GVR’s Internal Database
                        1.3.3. Secondary Sources
                        1.3.4. Primary Research
                        1.3.5. Details of Primary Research
                    1.4. Information or Data Analysis
                        1.4.1. Data Analysis Models
                    1.5. Market Formulation & Validation
                        1.5.1. Region Wise Market: Base Estimates
                        1.5.2. Global Market: CAGR Calculation
                    1.6. Model Details
                        1.6.1. Commodity Flow Analysis (Model 1)
                        1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
                        1.6.3. QFD Model Sizing & Forecasting (Model 3)
                        1.6.4. Bottom-Up Approach (Model 4)
                    1.7. Market Definitions
                    1.8. List of Secondary Sources
                    1.9. List of Abbreviations
                    1.10. Objectives
                        1.10.1. Objective - 1
                        1.10.2. Objective - 2
                        1.10.3. Objective - 3
                        1.10.4. Objective - 4
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights
Chapter 3. Pharmaceutical CDMO Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Market Dynamics
                        3.2.1. Market driver analysis
                            3.2.1.1. Growing consumption of biopharmaceuticals
                            3.2.1.2. Increasing demand for one-stop-shop CDMOs
                            3.2.1.3. Rising Demand for Advanced Therapeutics
                            3.2.1.4. Increasing outsourcing services by pharmaceutical companies
                            3.2.1.5. Upsurge in the number of clinical trials
                            3.2.1.6. Increasing pharmaceutical R&D investments
                            3.2.1.7. Growing demand for orphan drug discovery
                        3.2.2. Market restraint analysis
                            3.2.2.1. Compliance issues while outsourcing
                            3.2.2.2. Changing Scenarios within Developing Countries
                            3.2.2.3. Regulatory and Legal Compliance
                            3.2.2.4. Contractual Obligation
                    3.3. Pharmaceutical CDMO Market: Analysis Tools
                        3.3.1. PORTER’s Five Forces Analysis
                        3.3.2. PESTEL Analysis
                    3.4. Industry Ecosystem Analysis
                        3.4.1. Supply Chain Analysis
                        3.4.2. Demand Analysis
                        3.4.3. Raw Material Analysis
                            3.4.3.1. GMP Material
                                3.4.3.1.1. Regulatory Landscape
                                3.4.3.1.2. Adoption Trend Analysis
                                3.4.3.1.3. Consumer Behavior Analysis
                            3.4.3.2. Non-GMP Material
                                3.4.3.2.1. Regulatory Landscape
                                3.4.3.2.2. Adoption Trend Analysis
                                3.4.3.2.3. Consumer Behavior Analysis
                    3.5. Technology Landscape
                        3.5.1. Integration of AI in pharmaceutical CDMO market
                            3.5.1.1. Current Dynamics and Future Trends
                                3.5.1.1.1. Drug Discovery and Design
                                3.5.1.1.2. AI-Assisted Drug Active Pharmaceutical Ingredient (API) Synthesis
                                3.5.1.1.3. Process Optimization
                                3.5.1.1.4. Supply Chain Management
                                3.5.1.1.5. Clinical Trial Optimization
                                3.5.1.1.6. Regulatory Compliance
                    3.6. Total Number of Clinical Trials by Phase & Region (2021 - 2023)
                        3.6.1. Total Number of Clinical Trials by Phase (2021 - 2023)
                        3.6.2. Total Number of Clinical Trials by Region (2021 - 2023)
                            3.6.2.1. Percentage of Clinical Trials by Major Countries in North America:
                            3.6.2.2. Percentage of Clinical Trials by Major Countries in Europe:
                            3.6.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:
                            3.6.2.4. Percentage of Clinical Trials by Major Countries in Latin America:
                            3.6.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:
                        3.6.3. Total Number of Clinical Trials by Therapeutic Area (2021 - 2023)
                    3.7. COVID-19 Impact Analysis
Chapter 4. Pharmaceutical CDMO Market: Product Estimates & Trend Analysis
                    4.1. Segment Dashboard
                    4.2. Global Pharmaceutical CDMO Market Movement Analysis
                    4.3. Global Pharmaceutical CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
                        4.3.1. API
                            4.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
                            4.3.1.2. Type
                                4.3.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                                4.3.1.2.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
                                    4.3.1.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                                4.3.1.2.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
                                    4.3.1.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
                                4.3.1.2.4. Antibody Drug Conjugate (ADC)
                                    4.3.1.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
                                4.3.1.2.5. Others
                                    4.3.1.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
                            4.3.1.3. Synthesis
                                4.3.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
                                4.3.1.3.2. Synthetic
                                    4.3.1.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                                    4.3.1.3.2.2. Solid
                                        4.3.1.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                                    4.3.1.3.2.3. Liquid
                                        4.3.1.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
                                4.3.1.3.3. Biotech
                                    4.3.1.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
                            4.3.1.4. Drug
                                4.3.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
                                4.3.1.4.2. Innovative
                                    4.3.1.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                                4.3.1.4.3. Generics
                                    4.3.1.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
                            4.3.1.5. Manufacturing
                                4.3.1.5.1. Continuous manufacturing
                                    4.3.1.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
                                4.3.1.5.2. Batch manufacturing
                                    4.3.1.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        4.3.2. Drug Product
                            4.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                            4.3.2.2. Solid dosage
                                4.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                            4.3.2.3. Semi-solid dosage
                                4.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
                            4.3.2.4. Liquid dosage
                                4.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
                            4.3.2.5. Others
                                4.3.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Pharmaceutical CDMO Market: Workflow Estimates & Trend Analysis
                    5.1. Segment Dashboard
                    5.2. Global Pharmaceutical CDMO Market Movement Analysis
                    5.3. Global Pharmaceutical CDMO Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
                        5.3.1. Preclinical
                            5.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        5.3.2. Clinical
                            5.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        5.3.3. Commercial
                            5.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Pharmaceutical CDMO Market: Application Estimates & Trend Analysis
                    6.1. Segment Dashboard
                    6.2. Global Pharmaceutical CDMO Market Movement Analysis
                    6.3. Global Pharmaceutical CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
                        6.3.1. Oncology
                            6.3.1.1. Market estimates and forecast 2018 to 2030 (USD million)
                            6.3.1.2. Small Molecule
                                6.3.1.2.1. Market estimates and forecast 2018 to 2030 (USD million)
                            6.3.1.3. Biologics
                                6.3.1.3.1. Market estimates and forecast 2018 to 2030 (USD million)
                        6.3.2. Infectious Diseases
                            6.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.3. Neurological Disorders
                            6.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.4. Cardiovascular Diseases
                            6.3.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.5. Metabolic Disorders
                            6.3.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.6. Autoimmune Diseases
                            6.3.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.7. Respiratory Diseases
                            6.3.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.8. Ophthalmology
                            6.3.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.9. Gastrointestinal Disorders
                            6.3.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.10. Hormonal Disorders
                            6.3.10.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.11. Hematological Disorders
                            6.3.11.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        6.3.12. Others
                            6.3.12.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. Pharmaceutical CDMO Market: End Use Estimates & Trend Analysis
                    7.1. Segment Dashboard
                    7.2. Global Pharmaceutical CDMO Market Movement Analysis
                    7.3. Global Pharmaceutical CDMO Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
                        7.3.1. Small Pharmaceutical Companies
                            7.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        7.3.2. Medium Pharmaceutical Companies
                            7.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
                        7.3.3. Large Pharmaceutical Companies
                            7.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 8. Pharmaceutical CDMO Market: Regional Estimates & Trend Analysis by Product, Workflow, Application, & End Use
                    8.1. Regional Market Dashboard
                    8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
                    8.3. North America
                        8.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.3.2. U.S.
                            8.3.2.1. Key Country Dynamics
                            8.3.2.2. Competitive Scenario
                            8.3.2.3. Regulatory Scenario
                            8.3.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.3.3. Canada
                            8.3.3.1. Key Country Dynamics
                            8.3.3.2. Competitive Scenario
                            8.3.3.3. Regulatory Scenario
                            8.3.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.3.4. Mexico
                            8.3.4.1. Key Country Dynamics
                            8.3.4.2. Competitive Scenario
                            8.3.4.3. Regulatory Scenario
                            8.3.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                    8.4. Europe
                        8.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.4.2. UK
                            8.4.2.1. Key Country Dynamics
                            8.4.2.2. Competitive Scenario
                            8.4.2.3. Regulatory Scenario
                            8.4.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.4.3. Germany
                            8.4.3.1. Key Country Dynamics
                            8.4.3.2. Competitive Scenario
                            8.4.3.3. Regulatory Scenario
                            8.4.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.4.4. France
                            8.4.4.1. Key Country Dynamics
                            8.4.4.2. Competitive Scenario
                            8.4.4.3. Regulatory Scenario
                            8.4.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.4.5. Italy
                            8.4.5.1. Key Country Dynamics
                            8.4.5.2. Competitive Scenario
                            8.4.5.3. Regulatory Scenario
                            8.4.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.4.6. Spain
                            8.4.6.1. Key Country Dynamics
                            8.4.6.2. Competitive Scenario
                            8.4.6.3. Regulatory Scenario
                            8.4.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.4.7. Denmark
                            8.4.7.1. Key Country Dynamics
                            8.4.7.2. Competitive Scenario
                            8.4.7.3. Regulatory Scenario
                            8.4.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.4.8. Sweden
                            8.4.8.1. Key Country Dynamics
                            8.4.8.2. Competitive Scenario
                            8.4.8.3. Regulatory Scenario
                            8.4.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.4.9. Norway
                            8.4.9.1. Key Country Dynamics
                            8.4.9.2. Competitive Scenario
                            8.4.9.3. Regulatory Scenario
                            8.4.9.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                    8.5. Asia Pacific
                        8.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.5.2. China
                            8.5.2.1. Key Country Dynamics
                            8.5.2.2. Competitive Scenario
                            8.5.2.3. Regulatory Scenario
                            8.5.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.5.3. India
                            8.5.3.1. Key Country Dynamics
                            8.5.3.2. Competitive Scenario
                            8.5.3.3. Regulatory Scenario
                            8.5.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.5.4. Japan
                            8.5.4.1. Key Country Dynamics
                            8.5.4.2. Competitive Scenario
                            8.5.4.3. Regulatory Scenario
                            8.5.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.5.5. Australia
                            8.5.5.1. Key Country Dynamics
                            8.5.5.2. Competitive Scenario
                            8.5.5.3. Regulatory Scenario
                            8.5.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.5.6. South Korea
                            8.5.6.1. Key Country Dynamics
                            8.5.6.2. Competitive Scenario
                            8.5.6.3. Regulatory Scenario
                            8.5.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.5.7. Thailand
                            8.5.7.1. Key Country Dynamics
                            8.5.7.2. Competitive Scenario
                            8.5.7.3. Regulatory Scenario
                            8.5.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                    8.6. Latin America
                        8.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.6.2. Brazil
                            8.6.2.1. Key Country Dynamics
                            8.6.2.2. Competitive Scenario
                            8.6.2.3. Regulatory Scenario
                            8.6.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.6.3. Argentina
                            8.6.3.1. Key Country Dynamics
                            8.6.3.2. Competitive Scenario
                            8.6.3.3. Regulatory Scenario
                            8.6.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                    8.7. MEA
                        8.7.1. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.7.2. South Africa
                            8.7.2.1. Key Country Dynamics
                            8.7.2.2. Competitive Scenario
                            8.7.2.3. Regulatory Scenario
                            8.7.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.7.3. Saudi Arabia
                            8.7.3.1. Key Country Dynamics
                            8.7.3.2. Competitive Scenario
                            8.7.3.3. Regulatory Scenario
                            8.7.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.7.4. UAE
                            8.7.4.1. Key Country Dynamics
                            8.7.4.2. Competitive Scenario
                            8.7.4.3. Regulatory Scenario
                            8.7.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
                        8.7.5. Kuwait
                            8.7.5.1. Key Country Dynamics
                            8.7.5.2. Competitive Scenario
                            8.7.5.3. Regulatory Scenario
                            8.7.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
                    9.1. Company Categorization
                    9.2. Pharmaceutical CDMO Market Share/Assessment Analysis, 2023
                        9.2.1. Company Profiles
                        9.2.2. Lonza
                            9.2.2.1. Company overview
                            9.2.2.2. Financial performance
                            9.2.2.3. Product benchmarking
                            9.2.2.4. Strategic initiatives
                        9.2.3. Thermo Fisher Scientific, Inc.
                            9.2.3.1. Company overview
                            9.2.3.2. Financial performance
                            9.2.3.3. Product benchmarking
                            9.2.3.4. Strategic initiatives
                        9.2.4. Recipharm AB
                            9.2.4.1. Company overview
                            9.2.4.2. Financial performance
                            9.2.4.3. Product benchmarking
                            9.2.4.4. Strategic initiatives
                        9.2.5. Laboratory Corporation of America Holdings (LabCorp)
                            9.2.5.1. Company overview
                            9.2.5.2. Financial performance
                            9.2.5.3. Product benchmarking
                            9.2.5.4. Strategic initiatives
                        9.2.6. Catalent, Inc.
                            9.2.6.1. Company overview
                            9.2.6.2. Financial performance
                            9.2.6.3. Product benchmarking
                            9.2.6.4. Strategic initiatives
                        9.2.7. WuXi AppTec, Inc.
                            9.2.7.1. Company overview
                            9.2.7.2. Financial performance
                            9.2.7.3. Product benchmarking
                            9.2.7.4. Strategic initiatives
                        9.2.8. Samsung Biologics
                            9.2.8.1. Company overview
                            9.2.8.2. Financial performance
                            9.2.8.3. Product benchmarking
                            9.2.8.4. Strategic initiatives
                        9.2.9. Piramal Pharma Solutions
                            9.2.9.1. Company overview
                            9.2.9.2. Financial performance
                            9.2.9.3. Product benchmarking
                            9.2.9.4. Strategic initiatives
                        9.2.10. Siegfried Holding AG
                            9.2.10.1. Company overview
                            9.2.10.2. Financial performance
                            9.2.10.3. Product benchmarking
                            9.2.10.4. Strategic initiatives
                        9.2.11. CordenPharma International
                            9.2.11.1. Company overview
                            9.2.11.2. Financial performance
                            9.2.11.3. Product benchmarking
                            9.2.11.4. Strategic initiatives
                        9.2.12. Cambrex Corporation
                            9.2.12.1. Company overview
                            9.2.12.2. Financial performance
                            9.2.12.3. Product benchmarking
                            9.2.12.4. Strategic initiatives
                        9.2.13. Bushu Pharmaceuticals Ltd.
                            9.2.13.1. Company overview
                            9.2.13.2. Financial performance
                            9.2.13.3. Product benchmarking
                            9.2.13.4. Strategic initiatives
                        9.2.14. Nipro Corporation
                            9.2.14.1. Company overview
                            9.2.14.2. Financial performance
                            9.2.14.3. Product benchmarking
                            9.2.14.4. Strategic initiatives
                        9.2.15. Sequens
                            9.2.15.1. Company overview
                            9.2.15.2. Financial performance
                            9.2.15.3. Product benchmarking
                            9.2.15.4. Strategic initiatives
                        9.2.16. EuroAPI
                            9.2.16.1. Company overview
                            9.2.16.2. Financial performance
                            9.2.16.3. Product benchmarking
                            9.2.16.4. Strategic initiatives
                        9.2.17. Hovione
                            9.2.17.1. Company overview
                            9.2.17.2. Financial performance
                            9.2.17.3. Product benchmarking
                            9.2.17.4. Strategic initiatives
                        9.2.18. Axplora
                            9.2.18.1. Company overview
                            9.2.18.2. Financial performance
                            9.2.18.3. Product benchmarking
                            9.2.18.4. Strategic initiatives
                        9.2.19. Curia
                            9.2.19.1. Company overview
                            9.2.19.2. Financial performance
                            9.2.19.3. Product benchmarking
                            9.2.19.4. Strategic initiatives
                        9.2.20. Dottikon
                            9.2.20.1. Company overview
                            9.2.20.2. Financial performance
                            9.2.20.3. Product benchmarking
                            9.2.20.4. Strategic initiatives
                        9.2.21. Almac
                            9.2.21.1. Company overview
                            9.2.21.2. Financial performance
                            9.2.21.3. Product benchmarking
                            9.2.21.4. Strategic initiatives
                        9.2.22. FIS - Fabbrica Italiana Sintetici S.p.A.
                            9.2.22.1. Company overview
                            9.2.22.2. Financial performance
                            9.2.22.3. Product benchmarking
                            9.2.22.4. Strategic initiatives
                        9.2.23. Evonik
                            9.2.23.1. Company overview
                            9.2.23.2. Financial performance
                            9.2.23.3. Product benchmarking
                            9.2.23.4. Strategic initiatives
                        9.2.24. Carbogen Amcis
                            9.2.24.1. Company overview
                            9.2.24.2. Financial performance
                            9.2.24.3. Product benchmarking
                            9.2.24.4. Strategic initiatives
                        9.2.25. Farmhispania
                            9.2.25.1. Company overview
                            9.2.25.2. Financial performance
                            9.2.25.3. Product benchmarking
                            9.2.25.4. Strategic initiatives
                        9.2.26. Uquifa
                            9.2.26.1. Company overview
                            9.2.26.2. Financial performance
                            9.2.26.3. Product benchmarking
                            9.2.26.4. Strategic initiatives
                        9.2.27. Ajinomoto Bio-Pharma (Ajinomoto Co., Inc.)
                            9.2.27.1. Company overview
                            9.2.27.2. Financial performance
                            9.2.27.3. Product benchmarking
                            9.2.27.4. Strategic initiatives
                        9.2.28. Pfizer Centre One
                            9.2.28.1. Company overview
                            9.2.28.2. Financial performance
                            9.2.28.3. Product benchmarking
                            9.2.28.4. Strategic initiatives
                        9.2.29. Fareva
                            9.2.29.1. Company overview
                            9.2.29.2. Financial performance
                            9.2.29.3. Product benchmarking
                            9.2.29.4. Strategic initiatives
                        9.2.30. Sterling
                            9.2.30.1. Company overview
                            9.2.30.2. Financial performance
                            9.2.30.3. Product benchmarking
                            9.2.30.4. Strategic initiatives
                        9.2.31. Veranova
                            9.2.31.1. Company overview
                            9.2.31.2. Financial performance
                            9.2.31.3. Product benchmarking
                            9.2.31.4. Strategic initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 4 Global Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 5 Global Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 6 Global Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 7 Global Pharmaceutical CDMO, by Region, 2018 - 2030 (USD Million)
Table 8 North America Pharmaceutical CDMO, by Country, 2018 - 2030 (USD Million)
Table 9 North America Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 10 North America Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 11 North America Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 12 North America Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 13 U.S. Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 14 U.S. Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 15 U.S. Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 16 U.S. Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 17 Canada Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 18 Canada Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 19 Canada Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 20 Canada Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 21 Mexico Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 22 Mexico Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 23 Mexico Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 24 Mexico Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 25 Europe Pharmaceutical CDMO, by Country, 2018 - 2030 (USD Million)
Table 26 Europe Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 27 Europe Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 28 Europe Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 29 Europe Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 30 Germany Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 31 Germany Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 32 Germany Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 33 Germany Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 34 UK Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 35 UK Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 36 UK Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 37 UK Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 38 France Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 39 France Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 40 France Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 41 France Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 42 Italy Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 43 Italy Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 44 Italy Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 45 Italy Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 46 Spain Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 47 Spain Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 48 Spain Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 49 Spain Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 50 Denmark Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 51 Denmark Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 52 Denmark Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 53 Denmark Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 54 Sweden Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 55 Sweden Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 56 Sweden Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 57 Sweden Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 58 Norway Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 59 Norway Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 60 Norway Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 61 Norway Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 62 Asia Pacific Pharmaceutical CDMO, by Country, 2018 - 2030 (USD Million)
Table 63 Asia Pacific Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 64 Asia Pacific Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 65 Asia Pacific Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 66 Asia Pacific Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 67 China Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 68 China Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 69 China Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 70 China Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 71 Japan Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 72 Japan Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 73 Japan Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 74 Japan Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 75 India Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 76 India Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 77 India Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 78 India Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 79 South Korea Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 80 South Korea Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 81 South Korea Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 82 South Korea Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 83 Australia Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 84 Australia Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 85 Australia Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 86 Australia Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 87 Thailand Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 88 Thailand Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 89 Thailand Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 90 Thailand Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 91 Latin America Pharmaceutical CDMO, by Country, 2018 - 2030 (USD Million)
Table 92 Latin America Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 93 Latin America Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 94 Latin America Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 95 Latin America Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 96 Brazil Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 97 Brazil Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 98 Brazil Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 99 Brazil Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 100 Argentina Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 101 Argentina Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 102 Argentina Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 103 Argentina Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 104 Middle East & Africa Pharmaceutical CDMO, by Country, 2018 - 2030 (USD Million)
Table 105 Middle East & Africa Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 106 Middle East & Africa Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 107 Middle East & Africa Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 108 Middle East & Africa Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 109 South Africa Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 110 South Africa Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 111 South Africa Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 112 South Africa Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 115 Saudi Arabia Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 116 Saudi Arabia Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 117 UAE Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 118 UAE Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 119 UAE Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 120 UAE Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)
Table 121 Kuwait Pharmaceutical CDMO, by Product, 2018 - 2030 (USD Million)
Table 122 Kuwait Pharmaceutical CDMO, by Workflow, 2018 - 2030 (USD Million)
Table 123 Kuwait Pharmaceutical CDMO, by Application, 2018 - 2030 (USD Million)
Table 124 Kuwait Pharmaceutical CDMO, by End Use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Pharmaceutical CDMO, Market Segmentation
Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 10 Porter’s Five Forces Analysis
Fig. 11 Regional Marketplace: Key Takeaways
Fig. 12 Global Pharmaceutical CDMO, for API, 2018 - 2030 (USD Million)
Fig. 13 Global Pharmaceutical CDMO, for Type, 2018 - 2030 (USD Million)
Fig. 14 Global Pharmaceutical CDMO, for Traditional Active Pharmaceutical Ingredient (Traditional API), 2018 - 2030 (USD Million)
Fig. 15 Global Pharmaceutical CDMO, for Highly Potent Active Pharmaceutical Ingredient (HP-API), 2018 - 2030 (USD Million)
Fig. 16 Global Pharmaceutical CDMO, for Antibody Drug Conjugate (ADC), 2018 - 2030 (USD Million)
Fig. 17 Global Pharmaceutical CDMO, for Others, 2018 - 2030 (USD Million)
Fig. 18 Global Pharmaceutical CDMO, for Synthesis, 2018 - 2030 (USD Million)
Fig. 19 Global Pharmaceutical CDMO, for Synthetic, 2018 - 2030 (USD Million)
Fig. 20 Global Pharmaceutical CDMO, for Solid, 2018 - 2030 (USD Million)
Fig. 21 Global Pharmaceutical CDMO, for Liquid, 2018 - 2030 (USD Million)
Fig. 22 Global Pharmaceutical CDMO, for Biotech, 2018 - 2030 (USD Million)
Fig. 23 Global Pharmaceutical CDMO, for Drug, 2018 - 2030 (USD Million)
Fig. 24 Global Pharmaceutical CDMO, for Innovative, 2018 - 2030 (USD Million)
Fig. 25 Global Pharmaceutical CDMO, for Generics, 2018 - 2030 (USD Million)
Fig. 26 Global Pharmaceutical CDMO, for Manufacturing, 2018 - 2030 (USD Million)
Fig. 27 Global Pharmaceutical CDMO, for Continuous manufacturing, 2018 - 2030 (USD Million)
Fig. 28 Global Pharmaceutical CDMO, for Batch manufacturing, 2018 - 2030 (USD Million)
Fig. 29 Global Pharmaceutical CDMO, for Drug Product, 2018 - 2030 (USD Million)
Fig. 30 Global Pharmaceutical CDMO, for Solid dosage, 2018 - 2030 (USD Million)
Fig. 31 Global Pharmaceutical CDMO, for Tablets, 2018 - 2030 (USD Million)
Fig. 32 Global Pharmaceutical CDMO, for Capsules, 2018 - 2030 (USD Million)
Fig. 33 Global Pharmaceutical CDMO, for Powders & Granules, 2018 - 2030 (USD Million)
Fig. 34 Global Pharmaceutical CDMO, for Others, 2018 - 2030 (USD Million)
Fig. 35 Global Pharmaceutical CDMO, for Semi-solid dosage, 2018 - 2030 (USD Million)
Fig. 36 Global Pharmaceutical CDMO, for Cream, 2018 - 2030 (USD Million)
Fig. 37 Global Pharmaceutical CDMO, for Paste, 2018 - 2030 (USD Million)
Fig. 38 Global Pharmaceutical CDMO, for Gels, 2018 - 2030 (USD Million)
Fig. 39 Global Pharmaceutical CDMO, for Others, 2018 - 2030 (USD Million)
Fig. 40 Global Pharmaceutical CDMO, for Liquid dosage, 2018 - 2030 (USD Million)
Fig. 41 Global Pharmaceutical CDMO, for Injectables, 2018 - 2030 (USD Million)
Fig. 42 Global Pharmaceutical CDMO, for Suspensions, 2018 - 2030 (USD Million)
Fig. 43 Global Pharmaceutical CDMO, for Emulsion, 2018 - 2030 (USD Million)
Fig. 44 Global Pharmaceutical CDMO, for Others, 2018 - 2030 (USD Million)
Fig. 45 Global Pharmaceutical CDMO, for Preclinical, 2018 - 2030 (USD Million)
Fig. 46 Global Pharmaceutical CDMO, for Clinical, 2018 - 2030 (USD Million)
Fig. 47 Global Pharmaceutical CDMO, for Commercial, 2018 - 2030 (USD Million)
Fig. 48 Global Pharmaceutical CDMO, for Oncology, 2018 - 2030 (USD Million)
Fig. 49 Global Pharmaceutical CDMO, for Small Molecules, 2018 - 2030 (USD Million)
Fig. 50 Global Pharmaceutical CDMO, for Biologics, 2018 - 2030 (USD Million)
Fig. 51 Global Pharmaceutical CDMO, for Infectious Diseases, 2018 - 2030 (USD Million)
Fig. 52 Global Pharmaceutical CDMO, for Neurological Disorders, 2018 - 2030 (USD Million)
Fig. 53 Global Pharmaceutical CDMO, for Cardiovascular Disease, 2018 - 2030 (USD Million)
Fig. 54 Global Pharmaceutical CDMO, for Metabolic Disorders, 2018 - 2030 (USD Million)
Fig. 55 Global Pharmaceutical CDMO, for Autoimmune Diseases, 2018 - 2030 (USD Million)
Fig. 56 Global Pharmaceutical CDMO, for Respiratory Diseases, 2018 - 2030 (USD Million)
Fig. 57 Global Pharmaceutical CDMO, for Ophthalmology, 2018 - 2030 (USD Million)
Fig. 58 Global Pharmaceutical CDMO, for Gastrointestinal Disorders, 2018 - 2030 (USD Million)
Fig. 59 Global Pharmaceutical CDMO, for Hormonal Disorders, 2018 - 2030 (USD Million)
Fig. 60 Global Pharmaceutical CDMO, for Hematological Disorders, 2018 - 2030 (USD Million)
Fig. 61 Global Pharmaceutical CDMO, for Others, 2018 - 2030 (USD Million)
Fig. 62 Global Pharmaceutical CDMO, for Small Pharmaceutical Companies, 2018 - 2030 (USD Million)
Fig. 63 Global Pharmaceutical CDMO, for Medium Pharmaceutical Companies, 2018 - 2030 (USD Million)
Fig. 64 Global Pharmaceutical CDMO, for Large Pharmaceutical Companies, 2018 - 2030 (USD Million)
Fig. 65 Regional Outlook, 2023 & 2030
Fig. 66 North America Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 67 U.S. Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 68 Canada Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 69 Mexico Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 70 Europe Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 71 Germany Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 72 UK Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 73 France Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 74 Italy Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 75 Spain Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 76 Denmark Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 77 Sweden Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 78 Norway Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 79 Asia Pacific Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 80 Japan Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 81 China Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 82 India Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 83 Australia Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 84 South Korea Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 85 Thailand Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 86 Latin America Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 87 Brazil Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 88 Argentina Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 89 Middle East and Africa Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 90 South Africa Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 91 Saudi Arabia Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 92 UAE Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 93 Kuwait Pharmaceutical CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)